BrainsWay (neurostimulation system for the treatment of anxiety and depression)

2022: Announcement

On August 30, 2022, it became known that deep transcranial magnetic stimulation coils from BrainsWay were entering the market for the treatment of depression and anxiety.

BrainWay's deep transcranial magnetic stimulation (TMS) technology is carried out using coils that are mounted in a helmet. The helmet fits snugly to the patient's head and when the device is turned on, the coils create electromagnetic fields to non-invasively regulate brain activity associated with certain mental and neurological diseases.

A neurostimulation system has emerged to treat anxiety and depression

Previously, depressive anxiety and depression were only treated with an H1 coil. However, now, if this treatment method does not help, doctors can use the H7 coil, which stimulates another area of the brain - the anterior cingulate cortex, unlike the lateral prefrontal cortex H1, and is designed to have a deeper effect on the brain and cover a larger area of the organ than other TMS coils.

With the latest FDA authorization, healthcare providers already using the H7 coil to treat OCD can immediately begin using it to treat depressive anxiety and depression. BrainsWay said it will also begin rolling out a training program in the coming months to cover new readings of the system.

Clinicians are used to having multiple pharmaceuticals to make treatment plans for their patients, and expanding treatment options for depression with deep H7 coil TMS gives them another powerful non-drug tool, said Christopher von Jako, PhD, president and CEO of BrainsWay. However, like most other types of medical intervention, treatment of depression with TMS is not a universal solution for all anatomical targets.

We believe this authorization can contribute to our goal of allowing physicians to provide more personalized medicine for their patients based on what works best for each, he added.[1]

Notes